Roque Luís V, Dias Inês S, Cruz Nuno, Rebelo Ana, Roberto Amílcar, Rijo Patrícia, Reis Catarina P
CBiOS, Research Center for Biosciences and Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, Universidade de Lisboa, Lisbon, Portugal.
Skin Pharmacol Physiol. 2017;30(4):197-204. doi: 10.1159/000475473. Epub 2017 Jul 8.
BACKGROUND/AIMS: Androgenetic alopecia is an extremely common dermatological disorder affecting both men and women. Oral finasteride (FNS), a synthetic 4-aza-3-oxosteroid compound with poor aqueous solubility, blocks the peripheral conversion of testosterone to dihydrotestosterone (DHT) in a significant reduction in DHT concentration, achieving satisfactory results in alopecia treatment. However, its oral intake generally causes severe side effects. Considering that there is currently no scientifically proven treatment, new drug delivery systems able to improve alopecia therapy are urgently required.
In this study, polymeric nanoparticles have been proposed as a new carrier for topical delivery of FNS in hair follicles.
Polymeric nanoparticles, prepared by using a modified method of the emulsification/solvent diffusion, showed a mean particle size around 300 nm, which may be sufficient for reaching the dermis and hair follicles and negative zeta potential values. Scanning electron microscope measurements showed that all the polymeric nanoparticles exhibited a spherical shape and a smooth surface regardless of their composition. A high encapsulation efficiency was achieved for FNS (79.49 ± 0.47%). In vitro release assays in physiological conditions demonstrated that nanoparticles yielded a prolonged release of FNS for 3 h. Skin assays through an in vitro permeation study demonstrated that nanoparticles had low levels of penetration of FNS, improving its time residence onto the skin. All excipients used in nanoparticle composition and in 3 different vehicles were safe. These results suggest that the proposed novel formulation presents several good characteristics indicating its suitability for dermal delivery of FNS for alopecia treatment.
背景/目的:雄激素性脱发是一种极为常见的皮肤病,影响男性和女性。口服非那雄胺(FNS)是一种水溶性差的合成4-氮杂-3-氧代甾体化合物,可阻断睾酮向二氢睾酮(DHT)的外周转化,显著降低DHT浓度,在脱发治疗中取得了满意的效果。然而,口服通常会引起严重的副作用。鉴于目前尚无经科学验证的治疗方法,迫切需要能够改善脱发治疗的新药物递送系统。
在本研究中,聚合物纳米颗粒被提议作为FNS毛囊局部递送的新型载体。
采用改良的乳化/溶剂扩散法制备的聚合物纳米颗粒,平均粒径约为300nm,可能足以到达真皮和毛囊,且zeta电位为负值。扫描电子显微镜测量表明,所有聚合物纳米颗粒均呈球形且表面光滑,与它们的组成无关。FNS的包封率较高(79.49±0.47%)。生理条件下的体外释放试验表明,纳米颗粒使FNS的释放延长了3小时。通过体外渗透研究进行的皮肤试验表明,纳米颗粒对FNS的渗透水平较低,延长了其在皮肤上的停留时间。纳米颗粒组合物和3种不同载体中使用的所有辅料都是安全的。这些结果表明,所提出的新型制剂具有几个良好的特性,表明其适用于FNS的皮肤递送以治疗脱发。